Cell death is a highly regulated process required during development and throughout the lifetime of an organism in order to establish and maintain the functional capacity and homeostasis of various organs and to suppress tumor development. The regulation of cell death involves coordination between numerous signaling molecules, many of which are simultaneously involved in regulating cellular proliferation or survival pathways with tightly controlled crosstalk and feedback loops. Therefore, it is not surprising that the improper induction or malfunction of apoptotic cell death is manifested in a variety of diseases, including Alzheimer's disease, autoimmune diseases, Parkinson's disease, and cancer. Apoptosis is induced through an extrinsic pathway via activation of cell surface death receptors or through an intrinsic mechanism by depolarization of the mitochondrial membrane potential and increased levels of Ca 2+ ions. These result in the rapid activation of caspases 8 and 9, respectively (Jin and El-Deiry, 2005) . Considering that death is imminent once caspase cleavage is initiated, it is of paramount importance that the pathways that signal cell death be subject to precise control. Rangnekar and colleagues (Burikhanov et al., 2009) now describe an unexpected activity for Par-4 (prostate apoptosis response 4), previously known for its intracellular roles in promoting cell death. They show that in response to endoplasmic reticulum stress, Par-4 has an extracellular activity via TRAIL, a ligand that triggers the extrinsic apoptosis pathway (Figure 1) .
The regulator of apoptosis Par-4 has remained poorly understood, although in vivo data have implicated it in tumor suppression (Garcia-Cao et al., 2003; Zhao et al., 2007) . Its proapoptotic activity is attributed to the SAC (selective for apoptosis in cancer cells) domain, which is capable of nuclear translocation, caspase activation, inhibition of Bcl-2 expression, and downregulation of the transcription factor NF-kB. These They show that Par-4 is secreted and binds the ER stress chaperone protein GRP78 at the cell surface. Moreover, Par-4 and GRP78 are shown to be essential for TRAIL-induced apoptosis in several human cancer cell lines. Par-4 exists in the cytoplasm, endoplasmic reticulum, and nucleus and can be secreted in response to ER stress, thapsigargin, and tunicamycin in a Brefeldin A-sensitive manner. Surprisingly, GRP78, previously known as a prosurvival protein, is involved in Par-4-and TRAILinduced apoptotic signaling. TRAIL binds cell surface receptors such as DR5 and DR4, which recruit FADD and caspase 8 in a DISC (death-inducing signaling complex) to initiate extrinsic cell death. In the cytoplasm, Par-4 can be regulated by the kinases Akt and ζPKC and can inhibit the transcription factor NFκB to promote cell death. In the nucleus, Par-4 interacts with the transcription factor WT1 to inhibit the antiapoptotic protein Bcl2, and Par-4 also inhibits the topoisomerase TOP1. The ER stress pathway through the kinase PERK regulates eukaryotic translation initiation factor eIF2a to inhibit global protein translation while activating specific transcription and translation through ATF4 and CHOP. GRP78/BiP heterodimerizes with PERK in the ER and inhibits its activity. In an elegant series of experiments, the authors identify the chaperone GRP78 as a binding partner to Par-4 (specifically through its SAC domain) and show that this interaction is capable of initiating cell death dependent on FADD (Fas-associated protein with death domain). FADD is part of the death-inducing signaling complex (DISC). With coimmunoprecipitation, endogenous GRP78 is found to interact with intracellular Par-4 or its SAC domain. The authors hypothesize that GRP78 binds Par-4 prior to cell-surface translocation and subsequent secretion. Indeed, the two proteins colocalize at the ER under basal conditions, but after ER stress and prior to Par-4 secretion, GRP78 and Par-4 interact within cell surface membrane fractions. Secreted Par-4 subsequently induces apoptosis in a manner dependent on membranebound GRP78.
The involvement of GRP78 is especially intriguing given the opposing roles for GRP78 in both cell survival and cell death. Moderate levels of ER stress induce expression of chaperone proteins to promote cell survival in the presence of proteotoxicity; however, prolonged or extreme levels of ER stress result in the initiation of apoptosis. Par-4 secretion and its interaction with GRP78 may indicate a switch in the function of GRP78, from promoting cell survival to promoting cell death. The enhanced cell survival and chemoresistance conferred by GRP78 have been targeted for their therapeutic potential in cancer (Arap et al., 2004; Pyrko et al., 2007) . The findings of Burikhanov et al. suggest that the proapoptotic function of GRP78 makes it a less attractive target. In contrast, secreted Par-4 has tumor selective proapoptotic action and could represent a new therapeutic target for cancer.
One of the most studied and clinically relevant inducers of apoptosis is TRAIL (tumor necrosis factor-related apoptosis-inducing ligand) (Ashkenazi and Herbst, 2008) . TRAIL has also garnered significant attention in the context of ER stress. The induction of ER stress increases the expression of the TRAIL receptor DR5, which may explain why ER stressors, such as the protease inhibitor bortezomib, sensitize cells to TRAILinduced apotosis (Kandasamy and Kraft, 2008) . Enhanced TRAIL sensitivity has also been observed in Jurkat cells after Par-4 transfection (Boehrer et al., 2006) . Burikhanov et al. now show that Par-4 secretion is increased after treatment of PC-3 prostate cancer cells with TRAIL, whereas Par-4 secretion is not increased in benign BPH-1 cells with the same treatment. Using neutralizing antibodies for Par-4 and GRP78, the authors demonstrate that both secreted Par-4 and cell surface GRP78 are required for TRAIL-induced apoptosis in PC-3, H460, or HeLa cells. The upregulation of Par-4 by ER stress suggests a new means by which cells are sensitized to TRAIL. Although it remains to be seen whether Par-4 modulation can be used for therapeutic benefit, these findings do suggest that surface expression of Par-4 should be tested to prospectively identify TRAIL-sensitive tumors.
It is unclear how TRAIL induces Par-4 expression and how the interaction of Par-4 and GRP78 affects TRAILmediated formation of the DISC, which triggers caspase 8 activation, or influences the trafficking of TRAIL and its receptors. Because GRP78 is typically thought of as a prosurvival molecule, it will be of interest to determine in more detail the impact of Par-4 and TRAIL on the autophosphorylation of cell membrane-localized GRP78, as well as the impact of downstream signaling on cell death or survival. Studies investigating effects of Par-4 on the broader tumor necrosis factor (TNF) family will be of particular interest, given earlier studies by the Rangnekar group showing effects of Par-4 on Fas and FasL trafficking to induce apoptosis. Further studies of the coordinated effects of Par-4 on the TNF family may shed more light on Par-4 function in normal physiology, cell death, and cancer.
Tumor growth is a dynamic process driven by the relative contribution of aberrant cell proliferation signals (oncogenes) and cell death signaling (tumor suppressor genes). The increased incidence of spontaneous tumors in mice lacking Par-4 lends credence to the identification of Par-4 as a tumor suppressor protein. Given the clear requirement of GRP78/BiP in embryonic survival (Luo et al., 2006) , additional work, including its conditional deletion in somatic cells and tumors in vivo, is needed to further unravel its potential proapoptotic role in ER stress and extrinsic cell death pathways. Insensitivity or acquired resistance to apoptotic signaling contributes to the clinical resistance of malignant tumors to many standard chemotherapeutic agents. The use of small molecule and antibody therapeutics are increasingly attractive as alternative strategies to target resistant tumors; therefore, new findings in the field of apoptotic regulation, such as those described by Burikhanov et al., are extremely relevant to cancer therapeutics. In addition to identifying new targets, these findings may also lead to the development of assays that predict a tumor's response to treatment.
The reversible, covalent addition of ubiquitin to target proteins is a highly conserved and flexible regulatory mechanism. Monoubiquitination can change the activity of a ubiquinated target protein, whereas the addition of a ubiquitin chain can direct a protein to the 26S proteasome for rapid proteolytic degradation. Many proteins are modified by ubiquitin or ubiquitin-like proteins through the activity of the well-known E1-E2-E3 enzyme cascade, in which the E3 ubiquitin ligase binds the substrate and recruits the ubiquitin transferase activity of the E2 ubiquitin-conjugating enzyme. In humans, more than 500 predicted E3 ubiquitin ligases act on thousands of gene products and often recognize specifically modified forms of those proteins. Opposing this army of E3 ligases are ?95 deubiquitinating enzymes (DUBs), proteases that cleave the isopeptide bond between the C-terminal glycine of ubiquitin and a side-chain lysine of a target protein or ubiquitin itself (ReyesTurcu et al., 2009 ). There are five distinct DUB domains, of which one is a metalloprotease (JAMM domain) and four are cysteine proteases (USP, OTU, MJD, and UCH domains). It remains generally unclear how DUBs recognize their substrates. We also only have a modest understanding of the biological roles for most DUBs (Nijman et al., 2005) ; some have been linked to ubiquitin processing, histone modification, cell-cycle and DNA repair, kinase signaling, and endocytosis. With so much uncharted territory, how do we connect DUBs to their biology? In this issue of Cell, Sowa and colleagues (2009) approach this problem by purifying and identifying by mass spectrometry 774 high-confidence interacting proteins of 75 epitope-tagged DUBs (Figure 1 ). The authors further propose a standardized scoring method to quantify the confidence in the interactions they identify and to track improvements in the methodology itself.
The three keys to proteomic identification of interacting proteins are the selectivity of the purification, the accuracy of the mass spectrometric identification of proteins, and the bioinformatic and statistical analysis of the proteomic hits. How do Sowa and colleagues approach these steps? Using a retroviral expression vector, the authors establish stable cultured cell lines expressing hemagglutinin (HA) epitope-tagged versions of the DUBs. The tagged "bait" protein is immunoprecipitated along with interacting proteins from extracts of the cells by resin harboring anti-HA antibodies. These interacting proteins are cleaved into small fragments by trypsin, and duplicate samples from the purification are analyzed by liquid chromatography followed by tandem mass spectrometry (LC-MS/MS) ( Figure  1 ). With this standard single-epitope tag affinity purification scheme, substantial nonspecific interacting proteins are also isolated. These "background" interactions are partially corrected for by control purifications, including those with the other 74 DUBs. However, this purification approach may be improved by using two independent epitope tags and thus two sequential affinity purification steps to achieve a more selective purification. Another powerful method of stringent purification involves the specific isolation of correctly localized proteins in the cell with green fluorescent protein tags
